- Open Access
Case report of a young child with disseminated histoplasmosis and review of hyper immunoglobulin e syndrome (HIES)
- Wilson S Robinson†1, 2,
- Sandra R Arnold†1, 2,
- Christie F Michael1, 2,
- John D Vickery1,
- Robert A Schoumacher2,
- Eniko K Pivnick2,
- Jewell C Ward2,
- Vijaya Nagabhushanam3 and
- Dukhee B Lew1, 2Email author
© Robinson et al; licensee BioMed Central Ltd. 2011
- Received: 21 September 2011
- Accepted: 29 November 2011
- Published: 29 November 2011
Type 1 hyper IgE syndrome (HIES), also known as Job's Syndrome, is an autosomal dominant disorder due to defects in STAT3 signaling and Th17 differentiation. Symptoms may present during infancy but diagnosis is often made in childhood or later. HIES is characterized by immunologic and non-immunologic findings such as recurrent sinopulmonary infections, recurrent skin infections, multiple fractures, atopic dermatitis and characteristic facies. These manifestations are accompanied by elevated IgE levels and reduced IL-17 producing CD3+CD4+ T cells. Diagnosis in young children can be challenging as symptoms accumulate over time along with confounding clinical dilemmas. A NIH clinical HIES scoring system was developed in 1999, and a more recent scoring system with fewer but more pathogonomonic clinical findings was reported in 2010. These scoring systems can be used as tools to help in grading the likelihood of HIES diagnosis. We report a young child ultimately presenting with disseminated histoplasmosis and a novel STAT3 variant in the SH2 domain.
- Atopic Dermatitis
- Autosomal Recessive Form
- Central Nervous System Vasculitis
- Recurrent Sinopulmonary Infection
Type 1 hyper IgE syndrome (HIES) is an autosomal dominant disorder due to defects in signal transducer and activator of transcription 3 (STAT3) signaling [1, 2]. HIES was first described in 1966 and called Job's syndrome for the clinical manifestation of recurrent staphylococcal abscesses . The association with elevated IgE levels was discovered in 1972 and was referred to as Buckley syndrome  which was found to be the same condition as Job's syndrome. The genetic mutation of HIES was discovered in 2007. Minegishi et al. and Holland et al. reported heterozygous dominant-negative mutations in STAT3 in the DNA-binding and SH2 domains [5, 6]. STAT3 plays an important signaling role in Th17 differentiation.
Type 1 HIES is characterized by immunologic and non-immunologic findings. These manifestations are accompanied by elevated IgE levels and reduced IL-17 producing CD3+CD4+ T cells. Immunologic findings include newborn rash, recurrent sinopulmonary infections, recurrent skin infections, recurrent cyst-forming pneumonias, eczema, mucocutaneous fungal disease, eosinophilia and elevated IgE. Non-immunologic findings include characteristic face, retained primary teeth, multiple fractures, scoliosis, hyperextensibility, Chiari I malformations and craniosynostosis.
Diagnosis in young children can be challenging as symptoms accumulate over time along with confounding clinical dilemmas. A clinical HIES scoring system by the National Institutes of Health (NIH) was developed in 1999 . A more recent scoring system with fewer but more pathogonomonic clinical findings was reported in 2010 . These scoring systems can be used as tools to assess the likelihood of HIES diagnosis.
Also reported are autosomal recessive forms of HIES, i.e. defects in dedicator of cytokinesis 8 protein (DOCK8) and tyrosine kinase 2 (TYK2). These forms are less common, mostly described in consanguineous communities and have several different clinical distinctions.
This patient with wiry hair and square asymmetric face, was initially hospitalized at 5 months of age for pneumonia, multiple fractures, eczema with facial folliculitis but without cold abscess, wheezing, or milk allergy. Evaluation for non-accidental trauma was ongoing. Laboratory findings were as follows: IgE 187 IU/mL, IgA < 6.3 mg/dL, and eosinophil count 3,500/mm3. IgG, IgM, lymphocyte mitogen stimulation and cell surface markers were normal. Family history was noncontributory. His IgA normalized over the next 2 years. He had nine subsequent hospitalizations due to the following issues: rib fractures and pneumonia, respiratory distress secondary to subglottic cyst, gastroenteritis with dehydration, pneumonia requiring mechanical ventilation, severe dysphagia/aspiration pneumonia requiring G-Tube/Nissen fundoplication, and Streptococcus pneumoniae pneumonia with parapneumonic effusion. He also developed pneumatoceles and required left thoracotomy with bleb plication/pleurodesis. Other pertinent complications included recurrent ear infections and thrush, developmental delay, osteopenia, eczema, cellulitis, and allergic sensitization to egg, cat and dust mites. Further evaluation included normal chromosomes (46XY), CPK, vitamin D, calcium, PTH, and sweat chloride, along with negative HIV screening.
In July 2010, at 33 months of age, he presented with hepatosplenomegaly, hypoxia and respiratory distress. A diffuse opacity was seen on chest xray. Bronchoalveolar lavage showed extracellular and intracellular yeast suspicious for Histoplasma capsulatum. Disseminated histoplasmosis was confirmed by urine and serum antigen levels (both above measurable test limit).
Chronologic HIES scoring
IgE score (IU/ml)
Young age correction
6 × 2.5
8 × 2.5
4 × 3.33
8 × 3.33
Informed consent was obtained and approved by UTHSC IRB.
We report a case of disseminated histoplasmosis in a young child with STAT3-HIES [c.1772A > T, amino acid change p.Lys591Met]. Our patient's missense mutation in the SH2 domain has not been previously reported. Woellner et al. identified a missense mutation in the same amino acid [c.1771A > G, amino acid change p.Lys591Glu] but no clinical information is available .
AD-HIES is now defined by heterozygous mutation detection in STAT3 which contains 24 exons and 3 splice variants. STAT3 sequencing became commercially available in mid-2009 which provides the opportunity for more expedited and objective diagnosis but must be weighed by the level of clinical suspicion due to healthcare cost burden. Over 95% of AD-HIES have detectable STAT3 mutations and all domains have had mutations described including the N-terminal, coiled-coil, DNA-binding, linker, SH2 and transactivation domains.
Most of these mutations affect either the DNA-binding domain or the SH2 domain. Genotype-phenotype correlations involving most common domains and hotspots within these regions have been investigated . Sixty-five subjects (35 with DNA-binding domain mutation and 30 with SH2 domain mutation) were evaluated and suggest increased non-immunologic features in the SH2 domain group including high palate, increased interalar distance as well as increased scoliosis in a younger patient subset. They also showed a possible association with increased mortality risk secondary to infection as 6 of the 7 infection related deaths had DNA-binding domain mutations (five in the arginine 382 hotspot). Causative organisms were not reported but a trend of increased Varicella-Zoster reactivation was observed . Although these findings are suggestive, this sample size still lacks statistical power which has been true in other studies as well [10, 11]. Our patient has a mutation in SH2 domain and does not have the aforementioned non-immunologic findings, but over time they could develop.
Role in infection
Disseminated histoplasmosis in HIES is rare and not yet reported in young children. We found six case-reports total (5 patients) in the literature of histoplasma infection in HIES. Three had gastrointestinal tract disease (two teenagers and one adult) . One patient had laryngeal histoplasma only . The other case, reported twice, involves an adult male with budding yeast from a tongue ulcer and histoplasma cultured from right middle lobe infiltrate [11, 13]. Invasive fungal disease in HIES is typically seen in adults and attributed to lung damage from previous bacterial pneumonias . Our patient developed pneumatoceles following pneumococcal pneumonia that possibly served as a nidus for Histoplasma, which ultimately disseminated. There are reports of other invasive mycotic diseases . These cases suggest increased risk of disseminated fungal infection with endemic mycoses in HIES patients, raising the possibility that STAT3 has a role in intracellular infection.
Fungal pathogens are recognized by C-type lectin receptors (Dectin-1, Dectin-2, macrophage-inducible C-type lectin, mannose receptor), and there are recent reports indicating variants of either these receptors or down-stream signaling molecules will result in defective NFkB function. NFkB normally promotes IL1β, IL-6 and IL-23 cytokine production by macrophages . These macrophage cytokines facilitate STAT3 dependent Th17 cell differentiation. Th17 cells produce cytokines (i.e. IL-17, IL-21, IL-22) crucial for host defense against bacteria and fungi . Thus if STAT3 signaling is defective, as in HIES, Th17 differentiation is suppressed and there is resultant susceptibility to opportunistic infection .
HIES and chronic mucocutaneous disease (CMCD) share the clinical similarities of recurrent staphylococcal and candidal skin infections resulting from defective Th17 T cells. IL-17A and IL-17F are members of the IL-17 family that seem to play an important role in prevention of these infections. It has been recently reported that deficits in IL-17 production result in defective salivary activity due to antimicrobial protein impairment suggested to play a major role in initial fungal defense . In addition, IL-22 stimulation results in bolstering the innate response through its production of β-defensins. Recently described autosomal recessive defect in IL-17 receptor A (IL-17RA) and autosomal dominant defect in IL-17F are both associated with increased staphylococcal and candidal infections . In HIES, "cold boils" and recurrent pulmonary infections by Staphylococcus aureus or Haemophilus influenza are common.
A commonly described opportunistic fungal infection in primary immunodeficiency is Pneumocystis jiroveci although it is more often described in T-cell immunodeficiences. P jiroveci (formerly P carinii) is an extracellular fungus that has been described in several patients with HIES. Holland et al report seven HIES, HIV-negative patients with P jiroveci found in respiratory or pulmonary specimens . Those patients still living responded to appropriate therapy and were not continued on prophylaxis. Whether P jiroveci susceptibility in HIES is due to preceding chronic lung disease or immunologic abnormalities is not known. The IL-23-IL-17 cytokine axis is important in the murine model via IL-23 leading to increased production of IL-17 and IL-22 [19, 20]. Our patient did have BAL findings of extracellular yeast and thus was treated with three weeks of Bactrim, but he never had a definitive diagnosis of P jiroveci pneumonia.
As previously mentioned over 30 patients with HIES were used to develop a clinical scoring system in 1999 (NIH-HIES score) . A more recent scoring system (referred to as the HIES STAT3 score) published in February 2010 attempted to define clinical features that were better predicators of genotype . The authors studied over 100 patients with presumed HIES and IgE levels > 1,000 IU/mL to determine the five features that comprise their criteria: pneumonia, newborn rash, pathologic fractures, characteristic face of Job's syndrome and cathedral palate . The terminology used is more consistent with immunodeficiency diagnostic criteria of other more studied diseases.
The newer scoring system also utilizes Th17 cell counts in its diagnostic guidelines. Multiple groups have shown reduced Th17 cell counts expressed as percentage of CD4+ T cells in HIES [2, 10, 21, 22]. This test is not currently commercially available, but has been shown helpful in differentiating between HIES versus atopic dermatitis .
Our patient's clinical scoring was recorded over time and increased with sequential calculations. This trend exemplifies how patients accrue symptoms over time making early diagnosis in young children very difficult.
Defects in STAT3 signaling and its pathobiologic implications on immunologic and non-immunologic pathways will not completely manifest upon initial presentation. Development of additional symptoms over time is the expectation in HIES. For this reason, the NIH scoring system has a young age correction since certain parameters (i.e. multiple pneumonias, retention of primary teeth, scoliosis) will not be present until later in life. Young children can often have additional confounding co-morbidities that lead to unnecessary evaluations and delay in diagnosis.
Our patient's symptoms could be attributed to other possible etiologies. He had multiple rib fractures at different stages of healing that were suspicious for non-accidental trauma. With his osteopenia, he was predisposed to increased risk for fractures. Additionally, his multiple inhalant and food allergies could have contributed to eosinophilia and elevated IgE levels. Multiple pneumonias in children with gastroesophageal reflux are common due to aspiration. Our patient had severe reflux that required G-tube and Nissen fundoplication. As he was a late premature infant with a transiently low IgA level, increased risk for infection was expected. Both IgA and IL-17 responses are important in defense against fungi . Moreover, B cell immunoglobulin production and Th17 cells can be primed by Dectin-1 , although we have not investigated the Dectin-1 response in our patient.
There are many pediatric diagnoses much more common than HIES that could explain the aspects of our patient's presentation. Therefore, like our patient, young children are more prone to have a delay in diagnosis, whereas older children and adults will have accumulated more hallmark symptoms. The total IgE level can trend down to under 1,000 IU/mL, although values do not correlate well with disease activity or severity. Thus, clinical suspicion, coupled with scoring systems repeated over time can facilitate ultimate diagnosis.
As with most primary immunodeficiences without a cure, AD-HIES management focuses on preventative measures to limit the number and severity of infections. Our patient will remain on indefinite prophylactic antibiotic and antifungal therapy. Although he initially responded to booster with Prevnar 13, his immunity waned over 9 months to only one protective titer. Institution of prophylactic antibiotics targeted against pyogenic bacteria (namely Staphylococcus aureus) is paramount. Second-generation cephalosporins or trimethoprim/sulfamethoxazole are options for antibacterial prophylaxis; however, if lungs have structural damage, antimicrobial coverage is broadened to include Pseudomonas. History of fungal infection requires prophylactic treatment with fluconazole or itraconazole. Aggressive treatment at the earliest sign of infection is necessary to prevent serious illness. As these patients may have only mild symptoms due to impairment of acute phase cytokines (i.e. IL-6), symptoms may not correlate with severity of disease. As previously reported, routine PJP prophylaxis does not appear to be necessary . For patients with poor antibody production, IVIG can be considered. There are several case reports finding benefit in using IVIG for acute infection or prophylaxis, but no controlled studies exist at this time.
In addition to defects in the immune system, there are also non-immunologic disease manifestations that must be managed. Skin care focuses on reduction of bacterial colonization on the skin. Frequent bleach baths followed by moisturizing and adequate control of pruritus are recommended. Optimizing vitamin D and calcium intake is helpful for those patients with osteopenia. A predilection towards aneurysms makes blood pressure control important. Evaluation for retention of primary teeth and scoliosis in childhood is necessary. There should also be monitoring for signs and symptoms of lymphoma due to the increased incidence in AD-HIES. These patients have a chronic disease that can result in generalized or specific pain, depression, anxiety and fatigue. If chronic symptoms are affecting quality of life, then complementary medicine such as acupuncture can be attempted .
Hematopoietic stem cell transplant (HSCT) is generally ineffective in type 1 HIES [26, 27]. More recently, however, myeloablative allogeneic HSCT proved effective in two unrelated boys with AD-HIES and non-Hodgkin's lymphoma who continue to have normal immune reconstitution and no progression of non-immunologic manifestations at follow-up 10 and 14 years .
Autosomal recessive forms
Clinical and management features of different forms of HIES
Clinical distinctive characteristics
300-400 (in U.S.); 0.5-1 per million
Skeletal and dental abnormalities
Non-immunologic evaluation and treatment, prophylactic antibiotics +/- antifungals
1-2 (none in U.S.)
No pneumatoceles, recurrent viral infections, mycobacterial infection
Prophylactic antibiotics +/- antifungals +/- antivirals
Recurrent viral infections, food allergies/rhinitis, lymphopenia, increased risk of malignancy, CNS vasculitis
Prophylactic antibiotics and antivirals +/- antifungals, IVIG if antibody deficiency, allogeneic hematopoietic stem cell transplantation
Our patient and another patient previously reported by our group  were found to have significant inhalant and food sensitivity which is uncommon in AD-HIES. The previously reported case had IgE sensitization proven by skin and serum testing as well as clinical correlation by double-blind, placebo-controlled challenge to cow's milk. In both cases avoidance of milk protein and usage of elemental formula was an effective treatment.
This case underscores the inherent diagnostic difficulty of HIES in young children with confounding co-morbidities (food and inhalant allergies which are unusual features for STAT3-HIES, transiently low IgA, aspiration pneumonia, etc.). Clinical scoring systems establish threshold scores for HIES suspicion: 40 and 30+IgE > 1,000 IU/ml, in the NIH-HIES and HIES STAT3 systems, respectively [1, 2]. Utilizing clinical scoring systems and maintaining an appropriate level of suspicion, clinicians can determine when STAT3 mutation analysis is necessary. Availability of peripheral blood Th17 cell enumeration at a clinical diagnostic laboratory would allow for more expedient diagnosis and help to distinguish HIES from other diseases with elevated IgE, namely atopic dermatitis . Prophylactic therapy with antibacterial and antifungal agents (when indicated) are key points in patient management, along with regular monitoring of vaccine titers and proactive vaccination. This case of STAT3-HIES also highlights the inherent susceptibility of these patients to intracellular organisms endemic to the region (in our case, histoplasmosis). The clinical course and outcome for our patient may be instructive for other physicians managing patients with STAT3-HIES.
Authors thank Mr. Benjamin Efaw3 for his technical assistance in Th17 cell analysis and Drs. Russell W. Chesney and Karen L. Lakin for their clinical assistance.
- Grimbacher B, Schäffer AA, Holland SM, Davis J, Gallin JI, Malech HL: Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet. 1999, 65: 735-44.PubMed CentralView ArticlePubMedGoogle Scholar
- Woellner C, Gertz EM, Schaffer AA, Lagos M, Perro M, Glocker EO: Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol. 2010, 125: 424-32.PubMed CentralView ArticlePubMedGoogle Scholar
- Davis SD, Schaller J, Wedgewood RJ: Job's syndrome. Recurrent, "cold, " staphylococcal abscesses. Lancet. 1966, 1: 1013-15.View ArticlePubMedGoogle Scholar
- Buckley RH, Wray BB, Belmaker EZ: Extreme hyperimmunglobulin E and undue susceptibility to infection. Pediatrics. 1972, 49: 59-70.PubMedGoogle Scholar
- Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, Kawamura N, Ariga T, Pasic S, Stojkovic O, Metin A, Karasuyama H: Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007, 448: 1058-62.View ArticlePubMedGoogle Scholar
- Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML, Anderson VL, Darnell DN, Welch PA, Kuhns DB, Frucht DM, Malech HL, Gallin JI, Kobayashi SD, Whitney AR, Voyich JM, Musser JM, Woellner C, Schäffer AA, Puck JM, Grimbacher B: STAT3 mutations in the hyper-IgE syndrome. N Eng J Med. 2007, 357: 1608-19.View ArticleGoogle Scholar
- Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B: Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008, 205 (7): 1551-57.PubMed CentralView ArticlePubMedGoogle Scholar
- Kim H-J, Kim J-H, Shin YK, Lee S-I, Ahn K-M: A novel mutation in the linker domain of thesignal transducer and activator of transcription 3 gene, p.Lys531Glu, in hyper-IgE syndrome. J Allergy Clin Immuonol. 2009, 123: 956-58.View ArticleGoogle Scholar
- Heimall J, Davis J, Shaw PA, Hsu AP, Gu W, Welch P: Paucity of genotype-phenotype correlations in STAT3 mutation positive Hyper IgE Syndrome (HIES). Clin Immunol. 2011, 139 (1): 75-84.PubMed CentralView ArticlePubMedGoogle Scholar
- Renner ED, Rylaarsdam S, Aňover-Sombke S, Rack AL, Reichenbach J, Carey JC, Zhu Q, Jansson AF, Barboza J, Schimke LF, Leppert MF, Getz MM, Seger RA, Hill HR, Belohradsky BH, Torgerson TR, Ochs HD: Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced TH17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immuonol. 2008, 122: 181-87.View ArticleGoogle Scholar
- Vinh DC, Sugui JA, Hsu AP, Freeman AF, Holland SM: Invasive fungal disease in autosomal-dominant hyper-IgE syndrome. J Allergy Clin Immunol. 2010, 125: 1389-90.PubMed CentralView ArticlePubMedGoogle Scholar
- Steiner SJ, Kleiman MB, Corkins MR, Christenon JC, Wheat LJ: Ileocecal histoplasmosis simulating Crohn disease in a patient with hyperimmunoglobulin E syndrome. Pediatr Infect Dis J. 2009, 28: 744-46.View ArticlePubMedGoogle Scholar
- Desai K, Huston DP, Harriman GR: Previously undiagnosed hyper-IgE syndrome in an adult with multiple systemic fungal infections. J Allergy Clin Immunol. 1996, 98: 1123-24.View ArticlePubMedGoogle Scholar
- Powers AE, Bender JM, Kuma'novics A, Ampofo K, Augustine N, Pavia AT: Coccidiodes immitis meningitis in a patient with hyperimmunoglobulin E syndrome due to a novel mutation in a signal transducer and activator of transcription. Pediatr Infect Dis J. 2009, 28: 664-66.View ArticlePubMedGoogle Scholar
- Vautier S, de Sousa M, Brown G: C-type lectins, fungi and Th17 responses. Cytokine & Growth Factor Reviews. 2010, 21: 405-12.View ArticleGoogle Scholar
- Conti HR, Baker O, Freeman AF, Jang WS, Holland SM, Li RA, Edgerton M, Gaffen SL: New mechanism of oral immunity to mucosal candidiasis in hyper-IgE syndrome. Mucosal Immunology. 2011.Google Scholar
- Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman NM, Al-Muhsen S, Galicchio M, Abel L, Picard Capucine, Casanova JL: Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011, 332: 65-68.PubMed CentralView ArticlePubMedGoogle Scholar
- Freeman AF, Davis J, Anderson VL, Barson W, Darnell DN, Puck JM, Holland SM: Pneumocystis jiroveci infection in patients with hyper-IgE syndrome. Pediatrics. 2006, 118: e1271-75.View ArticlePubMedGoogle Scholar
- Rudner XL, Happel KI, Young EA, Shellito JE: Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infection and Immunity. 2007, 75: 3055-61.PubMed CentralView ArticlePubMedGoogle Scholar
- Shellito JE, Rudner X, Ruan S: Role of interleukin-23 in host defense against Pneumocystis carinii infection. Am J Respir Crit Care Med. 2010, 181: A5119.Google Scholar
- Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, Kanno Y, Spalding C, Elloumi HZ, Paulson ML, Davis J, Hsu A, Asher AI, O'Shea J, Holland SM, Paul WE, Douek DC: Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008, 452: 773-77.PubMed CentralView ArticlePubMedGoogle Scholar
- Schimke L, Sawalle-Belohradsky J, Roesler J, Wollenberg A, Rack A, Borte M: Diagnostic approach to the hyper-IgE syndromes: Immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. J Allergy Clin Immunol. 2010, 126: 611-17.View ArticlePubMedGoogle Scholar
- van Spriel AB, Sofi M, Gartlan KH, van der Schaaf A, Verschueren I, Torensma R, Raymakers RA, Loveland BE, Netea MG, Adema GJ, Wright MD, Figdor CG: The tetraspanin protein CD37 regulates IgA responses and anti-fungal immunity. PLoS Pathog. 2009, 5 (3): e1000338-Epub 2009 Mar 13.PubMed CentralView ArticlePubMedGoogle Scholar
- Agrawal S, Gupta S, Agrawal A: Human dendritic cells activated via dectin-1 are efficient at priming Th17, cytotoxic CD8 T and B cell responses. PLoS One. 2010, 5 (10): e13418.PubMed CentralView ArticlePubMedGoogle Scholar
- Ge AX, Ryan ME, Holland SM, Freeman AF, Anderson VL, Wang F, Fleshman JW: Acupuncture for symptom management in patients with hyper-IgE (Job's) syndrome. J Alternative & Complementary Med. 2011, 17 (1): 71-76.View ArticleGoogle Scholar
- Nester TA, Wagnon AH, Reilly WF, Spitzer G, Kjeldsberg CR, Hill HR: Effects of allogeneic peripheral stem cell transplantation in a patient with Job's syndrome of hyperimmunoglobulinemia E and recurrent infections. Am J Med. 1998, 108: 162-4.View ArticleGoogle Scholar
- Gennery AR, Flood TJ, Abinun M, Cant AJ: Bone marrow transplantation does not correct the hyper IgE syndrome. Bone Marrow Transplant. 2000, 25: 1303-5.View ArticlePubMedGoogle Scholar
- Goussetis E, Peristeri I, Kitra V, Traeger-Synodinos J, Theodosaki M, Psarra K, Kanariou M, Tzortzatou-Stathopoulou F, Petrakou E, Fylaktou I, Kanavakis E, Graphakos : Successful long-term immunologic reconstitution by allogeneic hematopoietic stem cell transplantation cures patients with autosomal dominant hyper-IgE syndrome. J Allergy Clin Immunol. 2010, 126: 392-94.View ArticlePubMedGoogle Scholar
- Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, Takada H, Hara T, Kawamura N, Ariga T, Kaneko H, Kondo N, Tsuge I, Yachie A, Sakiyama Y, Iwata T, Bessho F, Ohishi T, Joh K, Imai K, Kogawa K, Shinohara M, Fujieda M, Wakiguchi H, Pasic S, Abinum M, Nonoyama S, Karasuyama H: Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity. 2006, 25: 745-55.View ArticlePubMedGoogle Scholar
- Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, Matthews HF, Davis J, Turner ML, Uzel G, Holland SM, Su HC: Combined immunodeficiency associated with DOCK8 mutations. New Eng J of Med. 2009, 361: 2046-55.View ArticleGoogle Scholar
- Su H: Dedicator of cyokinesis 8 (DOCK8) deficiency. Curr Opin All & Clin Imm. 2010, 10: 515-20.View ArticleGoogle Scholar
- Bittner TC, Pannicke U, Renner ED, Notheis G, Hoffman F, Belohradsky BH, Wintergerst U, Hauser M, Klein B, Schwarz K, Schmid I, Albert MH: Successful long-term correction of autosomal recessive hyper-IgE syndrome due to DOCK8 deficiency by hematopoietic stem cell transplantation. Klin Padiatr. 2010, 222: 351-5.View ArticlePubMedGoogle Scholar
- McDonald DR, Massaad MJ, Johnston A, Keles S, Chatila T, Geha RS, Pai SY: Successful engraftment of donor marrow after allogeneic hematopoietic cell transplantation in autosomal-recessive hyper-IgE syndrome caused by dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol. 2010, 126: 1304-5.PubMed CentralView ArticlePubMedGoogle Scholar
- Barlogis V, Galambrun C, Chambost H, Lamoureux-Toth S, Petit P, Stephan JL, Michel G, Fischer A, Picard C: Successful allogeneic hematopoietic stem cell transplantation for DOCK8 deficiency. J Allergy Clin Immunol. 2011, [Epub].Google Scholar
- Hernandez-Trujillo VP, Nguyen WT, Belleau JT, Jeng M, Conley ME, Lew DB: Cow's milk allergy in a patient with hyper-IgE syndrome. Ann Allergy Asthma Immunol. 2004, 92 (4): 469-74.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.